+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bronchiectasis (Respiratory) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 123 Pages
  • August 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5438180
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide 'Bronchiectasis - Drugs In Development, 2021', provides an overview of the Bronchiectasis (Respiratory) pipeline landscape. Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights


This report provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 6, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionBronchiectasis - OverviewBronchiectasis - Therapeutics DevelopmentBronchiectasis - Therapeutics AssessmentBronchiectasis - Companies Involved in Therapeutics DevelopmentBronchiectasis - Drug ProfilesBronchiectasis - Dormant Projects
Bronchiectasis - Discontinued Products
  • Bronchiectasis - Product Development Milestonesh

Appendix
List of Tables
  • Number of Products under Development for Bronchiectasis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Bronchiectasis - Pipeline by Alaxia SAS, 2021
  • Bronchiectasis - Pipeline by Alitair Pharmaceuticals Inc, 2021
  • Bronchiectasis - Pipeline by Armata Pharmaceuticals, 2021
  • Bronchiectasis - Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Bronchiectasis - Pipeline by Chiesi Farmaceutici SpA, 2021
  • Bronchiectasis - Pipeline by Cila Therapeutics, 2021
  • Bronchiectasis - Pipeline by CSL Ltd, 2021
  • Bronchiectasis - Pipeline by Destiny Pharma Plc, 2021
  • Bronchiectasis - Pipeline by Helperby Therapeutics Group Ltd, 2021
  • Bronchiectasis - Pipeline by Insmed Inc, 2021
  • Bronchiectasis - Pipeline by Kamada Pharmaceuticals, 2021
  • Bronchiectasis - Dormant Projects, 2021
  • Bronchiectasis - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Bronchiectasis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alaxia SAS
  • Alitair Pharmaceuticals Inc
  • Armata Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cila Therapeutics
  • CSL Ltd
  • Destiny Pharma Plc
  • Helperby Therapeutics Group Ltd
  • Insmed Inc
  • Kamada Pharmaceuticals
  • Kyowa Kirin Co Ltd
  • MDI Therapeutics Inc
  • Novabiotics Ltd
  • Novartis AG
  • OrPro Therapeutics Inc
  • Parion Sciences Inc
  • Polyphor Ltd
  • PureIMS BV
  • Recipharm AB
  • Renovion Inc
  • Santhera Pharmaceuticals Holding AG